SELLAS Life Sciences to Host Shareholder Update Call on June 3rd
May 11 2021 - 7:30AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or
the “Company”), a late-stage clinical biopharmaceutical
company focused on developing novel cancer immunotherapies for a
broad range of indications, today announced that it will host a
Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.
The call will be facilitated by SELLAS’ President
& CEO, Angelos Stergiou, MD, ScD. h.c., who will provide a
corporate update.
Event: |
Shareholder
Update Call |
Date: |
Thursday,
June 3, 2021 |
Time: |
8:30 a.m.
ET |
Live
Call: |
1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779
(International) |
Webcast: |
https://www.sellaslifesciences.com/investors/events-and-presentations |
For interested individuals unable to join the
conference call, a replay of the call will be available through
June 17, 2021, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671
(International). Participants must use the following code to access
the replay of the call: 13719788. The online archive of the webcast
will be available at
https://www.sellaslifesciences.com/investors/events-and-presentations
after the conclusion of the call. About SELLAS Life
Sciences Group, Inc. SELLAS is a late-stage clinical
biopharmaceutical company focused on developing novel cancer
immunotherapeutics for a broad range of indications. SELLAS’ lead
product candidate, galinpepimut-S (GPS), is licensed from Memorial
Sloan Kettering Cancer Center and targets the WT1 protein, which is
present in an array of tumor types. GPS has potential both as a
monotherapy and in combination to address a broad spectrum of
hematologic malignancies and solid tumor indications. SELLAS’
second product candidate, nelipepimut-S (NPS), is a HER2-directed
cancer immunotherapy with potential to treat patients with
early-stage breast cancer with low to intermediate HER2 expression,
otherwise known as HER2 1+ or 2+, which includes TNBC patients,
following the standard of care.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Forward-Looking Statements This
press release contains forward-looking statements. All statements
other than statements of historical facts are “forward-looking
statements,” including those relating to future events Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of
various important factors. The forward-looking statements herein
are made only as of the date hereof. SELLAS undertakes no
obligation to update or supplement any forward-looking statements
to reflect actual results, new information, future events, changes
in its expectations or other circumstances that exist after the
date as of which the forward-looking statements were made.
For more information, please
contact:
Investor Contacts Valter Pinto /
Allison Soss KCSA Strategic Communications
Email: SELLAS@kcsa.com Phone: 914.907.2675 / 215.272.2707
Media Contacts Caitlin Kasunich /
Raquel Cona KCSA Strategic Communications
Email: SELLAS@kcsa.com Phone: 212.896.1241 / 212.896.1276
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024